Trellis™ · Sample · Not a live engagement
Regulatory Barrier & Data Gap Report
Client: Northbridge Ferments LLC (fictional) · Pathway focus: FDA GRAS / possible NDI overlap
Prepared: Sample date · Window: 3–6 weeks from complete intake
1. Executive summary
Based solely on materials supplied by the client, the primary federal pathway for the described precision-fermentation protein ingredient is FDA GRAS (self-determination with optional notice). A parallel NDI path is unlikely if the intended use is conventional food rather than a dietary supplement. Three material data gaps block a submission-ready dossier today.
2. Agency map
- FDA CFSAN — GRAS: Primary. Identity, manufacturing, exposure, and toxicology synthesis required.
- FDA NDI: Only if positioning shifts to supplement; not indicated on current intake.
- EPA / USDA: Not indicated for this finished food ingredient use case.
- State Ag: No separate registration flagged for this ingredient class in the sample scenario.
3. Certificate of Analysis review (redacted)
Two batch CoAs (Lab “Eurofins-style”, ISO/IEC 17025 claimed) were reviewed. Heavy metals panels present for Pb/As/Cd/Hg; microbial panel present. Gaps:
- Third non-consecutive batch CoA not provided
- Yeast and mold reported combined on Batch B — split required for GRAS tables
- No residual solvent panel for the extraction step described in intake
4. Priority roadmap (next 90 days)
- Commission Batch C CoA + residual solvents on the same method set
- Request lab reissue of Batch B with yeast and mold separated
- Lock intended use levels and food categories for exposure modeling
- Decide GRAS self-determination vs FDA notice path with counsel